{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:27:27Z","timestamp":1793975247088,"version":"4.8.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2017\/01\/X\/NZ7\/00364"],"award-info":[{"award-number":["2017\/01\/X\/NZ7\/00364"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40265-018-0947-x","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T06:58:41Z","timestamp":1531378721000},"page":"1105-1112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-1109","authenticated-orcid":false,"given":"Dorota","family":"Danielak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kara\u017aniewicz-\u0141ada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franciszek","family":"G\u0142\u00f3wka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"947_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/14656566.2017.1421634","volume":"19","author":"D Danielak","year":"2018","unstructured":"Danielak D, Kara\u017aniewicz-\u0141ada M, G\u0142\u00f3wka F. Ticagrelor in modern cardiology\u2014an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Expert Opin Pharmacother. 2018;19:103\u201312.","journal-title":"Expert Opin Pharmacother"},{"key":"947_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"947_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082\u2013115.","journal-title":"J Am Coll Cardiol"},{"key":"947_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267\u2013315.","journal-title":"Eur Heart J"},{"key":"947_CR5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","volume":"67","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395\u2013410.","journal-title":"J Am Coll Cardiol"},{"key":"947_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96:470\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"947_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","volume":"168","author":"HV Ganga","year":"2014","unstructured":"Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6\u201315.","journal-title":"Am Heart J"},{"key":"947_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jacl.2012.06.006","volume":"7","author":"MJ Cziraky","year":"2013","unstructured":"Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013;7:102\u20138.","journal-title":"J Clin Lipidol."},{"key":"947_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MOL.0000000000000174","volume":"26","author":"BA Taylor","year":"2015","unstructured":"Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol. 2015;26:221\u20137.","journal-title":"Curr Opin Lipidol"},{"key":"947_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","volume":"79","author":"M Hermann","year":"2006","unstructured":"Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther. 2006;79:532\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"947_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"947_CR12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ahj.2012.08.017","volume":"164","author":"A Akerblom","year":"2012","unstructured":"Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Horrow J, et al. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients\u2014results from the PLATelet inhibition and patient Outcomes (PLATO) study. Am Heart J. 2012;164:728\u201334.","journal-title":"Am Heart J"},{"key":"947_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122:1056\u201367.","journal-title":"Circulation"},{"key":"947_CR14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1177\/0091270011415526","volume":"52","author":"K Butler","year":"2012","unstructured":"Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012;52:1388\u201398.","journal-title":"J Clin Pharmacol"},{"key":"947_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00228-012-1369-4","volume":"69","author":"R Teng","year":"2013","unstructured":"Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:477\u201387.","journal-title":"Eur J Clin Pharmacol"},{"key":"947_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s002280100329","volume":"57","author":"M Igel","year":"2001","unstructured":"Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol. 2001;57:357\u201364.","journal-title":"Eur J Clin Pharmacol"},{"key":"947_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/dmd.110.037143","volume":"39","author":"D Zhou","year":"2011","unstructured":"Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos Biol Fate Chem. 2011;39:703\u201310.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR18","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.110.032250","volume":"38","author":"R Teng","year":"2010","unstructured":"Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos Biol Fate Chem. 2010;38:1514\u201321.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bph.12108","volume":"169","author":"A Sugidachi","year":"2013","unstructured":"Sugidachi A, Ohno K, Ogawa T, Jakubowski J, Hashimoto M, Tomizawa A. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013;169:82\u20139.","journal-title":"Br J Pharmacol"},{"key":"947_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3\u201311.","journal-title":"Pharmacol Res"},{"key":"947_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00044011-200121090-00006","volume":"21","author":"TB Vree","year":"2001","unstructured":"Vree TB, Dammers E, Ulc I, Horkovics-Kovats S, Ryska M, Merkx I. Variable plasma\/liver and tissue esterase hydrolysis of simvastatin in healthy volunteers after a single oral dose. Clin Drug Investig. 2001;21:643\u201352.","journal-title":"Clin Drug Investig."},{"key":"947_CR22","first-page":"1191","volume":"25","author":"T Prueksaritanont","year":"1997","unstructured":"Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos Biol Fate Chem. 1997;25:1191\u20139.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR23","first-page":"216","volume":"77","author":"T Zhang","year":"2015","unstructured":"Zhang T. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2015;77:216\u201329.","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci."},{"key":"947_CR24","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0090-9556(24)15086-6","volume":"28","author":"W Jacobsen","year":"2000","unstructured":"Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos Biol Fate Chem. 2000;28:1369\u201378.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","volume":"42","author":"H Lennern\u00e4s","year":"2003","unstructured":"Lennern\u00e4s H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42:1141\u201360.","journal-title":"Clin Pharmacokinet"},{"key":"947_CR26","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25:2822\u201335.","journal-title":"Clin Ther"},{"key":"947_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1527-3466.2002.tb00099.x","volume":"20","author":"AG Olsson","year":"2002","unstructured":"Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002;20:303\u201328.","journal-title":"Cardiovasc Drug Rev"},{"key":"947_CR28","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","volume":"36","author":"C Varenhorst","year":"2015","unstructured":"Varenhorst C, Eriksson N, Johansson \u00c5, Barratt BJ, Hagstr\u00f6m E, \u00c5kerblom A, et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36:1901\u201312.","journal-title":"Eur Heart J"},{"key":"947_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","volume":"447","author":"B Hagenbuch","year":"2004","unstructured":"Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP\/SLC21 family: phylogenetic classification as OATP\/SLCO superfamily, new nomenclature and molecular\/functional properties. Pflugers Arch. 2004;447:653\u201365.","journal-title":"Pflugers Arch"},{"key":"947_CR30","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","volume":"165","author":"M Roth","year":"2012","unstructured":"Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165:1260\u201387.","journal-title":"Br J Pharmacol"},{"key":"947_CR31","doi-asserted-by":"publisher","first-page":"G156","DOI":"10.1152\/ajpgi.2000.278.1.G156","volume":"278","author":"J K\u00f6nig","year":"2000","unstructured":"K\u00f6nig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 2000;278:G156\u201364.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"947_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11883-017-0701-y","volume":"19","author":"K Kellick","year":"2017","unstructured":"Kellick K. Organic ion transporters and statin drug interactions. Curr Atheroscler Rep. 2017;19:65.","journal-title":"Curr Atheroscler Rep."},{"key":"947_CR33","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1124\/dmd.108.021410","volume":"36","author":"S Kitamura","year":"2008","unstructured":"Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos Biol Fate Chem. 2008;36:2014\u201323.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al","year":"2008","unstructured":"SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N Engl J Med. 2008;359:789\u201399.","journal-title":"N Engl J Med"},{"key":"947_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/tpj.2010.92","volume":"12","author":"LR Brunham","year":"2012","unstructured":"Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenom J. 2012;12:233\u20137.","journal-title":"Pharmacogenom J."},{"key":"947_CR36","first-page":"365","volume":"72","author":"Y Wang","year":"2017","unstructured":"Wang Y, Tian Y, Lv P, Chen L, Luo W, Jing X, et al. The effect of SLCO1B1polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharm. 2017;72:365\u20138.","journal-title":"Pharm."},{"key":"947_CR37","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","volume":"165","author":"JS Danik","year":"2013","unstructured":"Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J. 2013;165:1008\u201314.","journal-title":"Am Heart J"},{"key":"947_CR38","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00228-017-2318-z","volume":"73","author":"J-E Liu","year":"2017","unstructured":"Liu J-E, Liu X-Y, Chen S, Zhang Y, Cai L-Y, Yang M, et al. SLCO1B1 521T\u2009>\u2009C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol. 2017;73:1409\u201316.","journal-title":"Eur J Clin Pharmacol"},{"key":"947_CR39","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","volume":"61","author":"JD Wessler","year":"2013","unstructured":"Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495\u2013502.","journal-title":"J Am Coll Cardiol"},{"key":"947_CR40","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1023\/B:PHAM.0000041466.84653.8c","volume":"21","author":"JH Hochman","year":"2004","unstructured":"Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, et al. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004;21:1686\u201391.","journal-title":"Pharm Res"},{"key":"947_CR41","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1734-1140(11)70582-5","volume":"63","author":"D-H Choi","year":"2011","unstructured":"Choi D-H, Choi J-S, Li C, Choi J-S. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. Pharmacol Rep. 2011;63:1574\u201382.","journal-title":"Pharmacol Rep"},{"key":"947_CR42","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/ijc.24885","volume":"126","author":"E Sieczkowski","year":"2010","unstructured":"Sieczkowski E, Lehner C, Ambros PF, Hohenegger M. Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010;126:2025\u201335.","journal-title":"Int J Cancer"},{"key":"947_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/clpt.2008.25","volume":"84","author":"JE Keskitalo","year":"2008","unstructured":"Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther. 2008;84:457\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"947_CR44","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1124\/dmd.107.015677","volume":"35","author":"C Chen","year":"2007","unstructured":"Chen C, Lin J, Smolarek T, Tremaine L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a\/b knockout and wild-type mice. Drug Metab Dispos Biol Fate Chem. 2007;35:1725\u20139.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR45","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1124\/dmd.104.002477","volume":"33","author":"C Chen","year":"2005","unstructured":"Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos Biol Fate Chem. 2005;33:537\u201346.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR46","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s11095-005-9371-5","volume":"23","author":"T Sakaeda","year":"2006","unstructured":"Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin J-S, Iwaki K, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006;23:506\u201312.","journal-title":"Pharm Res"},{"key":"947_CR47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.17305\/bjbms.2014.3.43","volume":"14","author":"A Sa\u0142acka","year":"2014","unstructured":"Sa\u0142acka A, Bi\u0144czak-Kuleta A, Kaczmarczyk M, Hornowska I, Safranow K. Clark JSC. Possible association of ABCB1:c.3435T\u2009>\u2009C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment\u2013a pilot study. Bosn J Basic Med Sci. 2014;14:144\u20139.","journal-title":"Bosn J Basic Med Sci."},{"key":"947_CR48","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2217\/pgs.09.105","volume":"10","author":"ML Becker","year":"2009","unstructured":"Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics. 2009;10:1743\u201351.","journal-title":"Pharmacogenomics."},{"key":"947_CR49","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1002\/ijc.25295","volume":"127","author":"CA Goard","year":"2010","unstructured":"Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, et al. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer. 2010;127:2936\u201348.","journal-title":"Int J Cancer"},{"key":"947_CR50","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2125.2009.03440.x","volume":"68","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol. 2009;68:207\u201313.","journal-title":"Br J Clin Pharmacol"},{"key":"947_CR51","unstructured":"Zhou Q, Ruan Z-R, Yuan H, Xu D-H, Zeng S. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c\u2009>\u2009A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Pharm. 2013;68:129\u201334."},{"key":"947_CR52","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00228-013-1543-3","volume":"69","author":"R Teng","year":"2013","unstructured":"Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:1801\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"947_CR53","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/fcp.12219","volume":"30","author":"N Marsousi","year":"2016","unstructured":"Marsousi N, Doffey-Lazeyras F, Rudaz S, Desmeules JA, Daali Y. Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells. Fundam Clin Pharmacol. 2016;30:577\u201384.","journal-title":"Fundam Clin Pharmacol"},{"key":"947_CR54","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. The Lancet. 2010;376:1320\u20138.","journal-title":"The Lancet."},{"key":"947_CR55","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1124\/dmd.107.015230","volume":"35","author":"TC Goosen","year":"2007","unstructured":"Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, et al. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos Biol Fate Chem. 2007;35:1315\u201324.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR56","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1124\/jpet.301.3.1042","volume":"301","author":"T Prueksaritanont","year":"2002","unstructured":"Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002;301:1042\u201351.","journal-title":"J Pharmacol Exp Ther"},{"key":"947_CR57","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","volume":"30","author":"T Prueksaritanont","year":"2002","unstructured":"Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos Biol Fate Chem. 2002;30:1280\u20137.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR58","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1124\/dmd.104.000794","volume":"32","author":"JA Williams","year":"2004","unstructured":"Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. Drug Metab Dispos Biol Fate Chem. 2004;32:1201\u20138.","journal-title":"Drug Metab Dispos Biol Fate Chem."},{"key":"947_CR59","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.12659\/AJCR.905974","volume":"18","author":"SM Mrotzek","year":"2017","unstructured":"Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor leads to statin-induced rhabdomyolysis: a case report. Am J Case Rep. 2017;18:1238\u201341.","journal-title":"Am J Case Rep."},{"key":"947_CR60","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1331\/JAPhA.2015.14151","volume":"55","author":"K Kido","year":"2015","unstructured":"Kido K, Wheeler MB, Seratnahaei A, Bailey A, Bain JA. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. J Am Pharm Assoc JAPhA. 2015;55:320\u20133.","journal-title":"J Am Pharm Assoc JAPhA."},{"key":"947_CR61","first-page":"3801819","volume":"2017","author":"I Banakh","year":"2017","unstructured":"Banakh I, Haji K, Kung R, Gupta S, Tiruvoipati R. Severe rhabdomyolysis due to presumed drug interactions between atorvastatin with amlodipine and ticagrelor. Case Rep Crit Care. 2017;2017:3801819.","journal-title":"Case Rep Crit Care."},{"key":"947_CR62","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.medcli.2015.11.032","volume":"146","author":"R Cenjor Mart\u00edn","year":"2016","unstructured":"Cenjor Mart\u00edn R, Guti\u00e9rrez-Madrid E, Mart\u00edn-S\u00e1nchez FJ, Cuervo Pinto R. Iatrogenic rhabdomyolysis in a patient with ischemic heart disease. Med Clin (Barc). 2016;146:e57\u20138.","journal-title":"Med Clin (Barc)."},{"key":"947_CR63","unstructured":"Sarinic VM, Sandberg L, Hartman J, Caduff-Janosa P. Interaction between rosuvastatin and ticagrelor resulting in rhabdomyolysis. Upps. Monit. Cent. 2017. https:\/\/www.who-umc.org\/media\/164007\/rhabdomyolysisweb.pdf . Accessed 4 Mar 2018."},{"key":"947_CR64","first-page":"136","volume":"73","author":"AJ Vuren van","year":"2015","unstructured":"van Vuren AJ, de Jong B, Bootsma HPR, Van der Veen MJ, Feith GW. Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis. Neth J Med. 2015;73:136\u20138.","journal-title":"Neth J Med"},{"key":"947_CR65","first-page":"e1633","volume":"9","author":"G Samuel","year":"2017","unstructured":"Samuel G, Atanda AC, Onyemeh A, Awan A, Ajiboye O. A unique case of drug interaction between ticagrelor and statin leading to acute renal failure. Cureus. 2017;9:e1633.","journal-title":"Cureus."},{"key":"947_CR66","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2165\/00002018-200629110-00005","volume":"29","author":"KJ Ronaldson","year":"2006","unstructured":"Ronaldson KJ, O\u2019Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf. 2006;29:1061\u20137.","journal-title":"Drug Saf"},{"key":"947_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2016.05.015","volume":"179","author":"H Khine","year":"2016","unstructured":"Khine H, Yuet WC, Adams-Huet B, Ahmad Z. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J. 2016;179:1\u20139.","journal-title":"Am Heart J"},{"key":"947_CR68","unstructured":"ZOCOR (simvastatin) Tablets\u2014product information. merck.com. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zocor\/zocor_pi.pdf . Accessed 4 Mar 2018."},{"key":"947_CR69","unstructured":"Lipitor (atorvastatin calcium)\u2014product information. pfizer.com. http:\/\/www.pfizer.com.au\/sites\/g\/files\/g10005016\/f\/201311\/PI_Lipitor_355.pdf . Accessed 4 Mar 2018."},{"key":"947_CR70","unstructured":"Crestor (rosuvastatin calcium)\u2014product monograph. astrazeneca.ca. https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/crestor-product-monograph-en.pdf . Accessed 4 Mar 2018."},{"key":"947_CR71","unstructured":"BRILINTA (ticagrelor)\u2014Product Monograph. astrazeneca.ca. https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/BRILINTA%20-%20Product-Monograph.pdf . Accessed 4 Mar 2018."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0947-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0947-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0947-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T19:01:01Z","timestamp":1751742061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0947-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0947-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"12 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by the National Science Centre, Poland, under Grant 2017\/01\/X\/NZ7\/00364.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dorota Danielak, Marta Kara\u017aniewicz-\u0141ada, and Franciszek G\u0142\u00f3wka declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}